Kimiyyar JBS da ke Pennsylvania ta fada a yau cewa ta sami kyautar gadar dala miliyan 3 don Binciken Ƙirƙirar Ƙirƙirar Ƙirƙirar Kasuwancin IIB daga Cibiyar Ciwon daji ta Ƙasa. Kamfanin ya ƙirƙiri samfurin biopsy na farko, wanda shine gwajin DNA na fitsari don ciwon daji na hanta na farko (HCC).
Despite the monitoring plan for high-risk groups (such as patients with chronic hepatitis, cirrhosis, and fatty liver disease), HCC is usually only discovered at an advanced stage. But if HCC can be detected early, the survival rate can be as high as 40%. Although the detection of the biomarker serum alpha-fetoprotein (AFP) currently shows sensitivity, there is still much room for improvement in the early screening of ciwon daji. The technology developed by JBS to separate cancer-derived DNA in urine, as well as a special PCR detection method, can more accurately and sensitively detect circulating tumo DNA biomarkers for liver cancer. In a blind pre-validation study, the company stated that if serum AFP is added, the sensitivity of the method will increase to 89%.
JBS ta ce ta hada kai da James Hamilton na Cibiyar Kiwon Lafiya ta Jami’ar Johns Hopkins da Hie-Won Hann na Asibitin Jami’ar Thomas don ci gaban gwajin fitsarin ciwon hanta.
https://www.genomeweb.com/molecular-diagnostics/jbs-science-awarded-3m-commercialize-liver-cancer-screening-test#.W62TzNczbIU
